Recursion Pharmaceuticals' stock rises on heavy trading volume, with investors eyeing its AI-designed cancer drug REC-3565 ...
We came across a bullish thesis on Recursion Pharmaceuticals, Inc. on Emil Hartela Investing’s Substack by Emil. In this article, we will summarize the bulls’ thesis on RXRX. Recursion Pharmaceuticals ...
TipRanks on MSN
Recursion Pharmaceuticals rises 17.9%
Recursion Pharmaceuticals (RXRX) is up 17.9%, or 93c to $6.17. Published first on TheFly – the ultimate source for real-time, market-moving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback